Due to their unique ability to prime and stimulate both CD8+ and CD4+ T cells, DCs loaded with whole tumor lysate have been investigated in several clinical trials for their ability to induce therapeutic anti-tumor T cell responses [1], [2], [3], [4], [5], [6], [7], [8]. This evidence concerns the gene CD8A and neoplasm.